臨床検査55巻11号

2011年10月発行

特集 ここまでわかった自己免疫疾患 各論 3．膠原病と類縁疾患

4) 強皮症

著者： 川口鎮司¹

所属機関： ¹東京女子医科大学附属膠原病リウマチ痛風センター

ページ範囲：P.1156 - P.1163

全身性強皮症は，皮膚の硬化だけでなく，血管病変の合併がほとんどの症例でみられる．その2種類の病態に同時に対応できる治療薬は今のところない．線維化に対しては，免疫抑制薬での治療となり，血管病変に関しては血管拡張薬での治療となる．この10年で，治療薬の有効性がかなり明確になってきた．線維化病変には，シクロホスファミドや他の免疫抑制薬，血管病変には，プロスタノイド，エンドセリン受容体拮抗薬，ホスホジエステラーゼ5阻害薬を用いることが多くなってきている．しかし，まだ治療に反応しない症例は多く，近い将来の病態解明と新規治療薬の開発が待たれる．

参考文献

1) Medsger TA Jr : Systemic sclerosis (scleroderma), localized forms of scleroderma, and calcinosis. In Arthritis and Allied Conditions : a textbook of rheumatology (McCarty DJ, Koopman WJ, eds), Lea ＆ Febiger, Philadelphia，pp1253-1292，1993

2) Medsger TA Jr, Masi AT : Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med　74：714-721，1971

3) Steen VD, Conte C, Santoro D, et al : Twenty year incidence survey of systemic sclerosis (scleroderma). Arthritis Rheum　23：581-590，1980

4) Bryan C, Knight C, Black CM, et al : Prediction of five-year survival following presentation with scleroderma : development of a simple model using three disease factors at first visit. Arthritis Rheum　42：2660-2665，1999

5) LeRoy EC : Increased collagen synthesis by scleroderma skin fibroblasts in vitro : a possible defect in the regulation or activation of the scleroderma fibroblasts. J Clin Invest　54：880-889，1974

6) Kulozik M, Hogg A, Lankat-Buttgereit B, et al : Co-localization of transforming growth factor beta2 with alpha1 (I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest　86：917-922，1990

7) Yamakage A, Kikuchi K, Smith EA, et al : Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med　175：1227-1234，1992

8) Igarashi A, Nashiro K, Kikuchi K, et al : Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol　105：280-284，1995

9) Kawaguchi Y : IL-1alpha gene expression and protein production by fibroblasts from patients with systemic sclerosis. Clin Exp Immunol　97：445-450，1994

10) Distler JH, Jüngel A, Caretto D, et al : Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum　54：214-225，2006

11) Jinnin M, Ihn H, Asano Y, et al : Upregulation of tenascin-C expression by IL-13 in human dermal fibroblasts via the phosphoinositide 3-kinase/Akt and the protein kinase C signaling pathways. J Invest Dermatol　126：551-560，2006

12) Kurasawa K, Hirose K, Sano H, et al : Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum　43：2455-2463，2000

13) Baroni SS, Santillo M, Bevilacqua F, et al : Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med　354：2667-2676，2006

14) Takagi K, Kawaguchi Y, Kawamoto M, et al. Activation of the activin A-ALK-Smad pathway in systemic sclerosis. J Autoimmun　36：181-188，2011

15) Kawaguchi Y, Nishimagi E, Tochimoto A, et al : Intracellular IL-1alpha-binding proteins contribute to biological functions of endogenous IL-1alpha in systemic sclerosis fibroblasts. Proc Natl Acad Sci USA　103：14501-14506，2006

16) Stewart DJ, Levy RD, Cernacek P, et al : Increased plasma endothelin-1 in pulmonary hypertension : marker or mediator of disease? Ann Intern Med　114：464-469，1991

17) Kuwana M, Okazaki Y, Yasuoka H, et al : Defective vasculogenesis in systemic sclerosis. Lancet　364：603-610，2004

18) Kuwana M, Kaburaki J, Okazaki Y, et al : Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum　54：1946-1951，2006

19) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum　23：581-590，1980

20) LeRoy EC, Black C, Fleischmajer R, et al : Scleroderma (systemic sclerosis) : classification, subsets and pathogenesis. J Rheumatol　15：202-205，1988

21) Medsger TA, Silman AJ, Steen VD, et al : Development of a severity index for systemic sclerosis. Arthritis Rheum　37：S260，1994

22) Okano Y, Steen VD, Medsger TA Jr : Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med　119：1005-1013，1993

23) Avouac J, Fransen J, Walker UA, et al : Preliminary criteria for the very early diagnosis of systemic sclerosis : results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis　70：476-481，2011

24) Matucci-Cerinic M, Denton CP, Furst DE, et al : Bosentan treatment of digital ulcers related to systemic sclerosis : results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis　70：32-38，2011

25) Brueckner CS, Becker MO, Kroencke T, et al : Effect of sildenafil on digital ulcers in systemic sclerosis : analysis from a single centre pilot study. Ann Rheum Dis　69：1475-1478，2010

26) Steen VD, Medsger TA Jr, Rodnan GP : D-penicillamine therapy in progressive systemic sclerosis (scleroderma) : a retrospective analysis. Ann Intern Med　97：652-659，1982

27) Brennan P, Silman A, Black C, et al : Reliability of skin involvement measures in scleroderma. The UK Scleroderma Study Group. Br J Rheumatol　31：457-460，1992

28) Kuwana M, Kaburaki J, Okano Y, et al : Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum　37：75-83，1994

29) Silver RM, Warrick JH, Kinsella MB, et al : Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol　20：838-844，1993

30) Várai G, Earle L, Jimenez SA, et al : A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol　25：1325-1329，1998

31) Tashkin DP, Elashoff R, Clements PJ, et al : Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med　354：2655-2666，2006

32) Hoyles RK, Ellis RW, Wellsbury J, et al : A multicenter, prospective, randomized, double-blind, placebo-controlled, trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum　54：3962-3970，2006

33) Tochimoto A, Kawaguchi Y, Hara M, et al : Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis : 4-year follow-up. Mod Rheumatol　21：296-301，2011

34) Kunieda T, Nakanishi N, Matsubara H, et al : Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension. Int Heart J　50：513-529，2009

35) Rubin LJ, Badesch DB, Barst RJ, et al : Bosentan therapy for pulmonary arterial hypertension. N Engl J Med　346：896-903，2002

36) Michelakis ED, Tymchak W, Noga M, et al : Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation　108：2066-2069，2003

37) Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation　119：2894-2903，2009

38) Moore HC, Sheehan HL : The kidney of scleroderma. Lancet　1：68-70，1952

39) Steen VD, Costantino JP, Shapiro AP, et al : Outcome of renal crisis in systemic sclerosis : relation to availability of angiotension converting enzyme (ACE) inhibitors. Ann Intern Med　113：352-357，1990

40) Steen VD, Medsger TA Jr : Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum　41：1613-1619，1998

41) Nishimagi E, Tochimoto A, Kawaguchi Y, et al : Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement. J Rheumatol　34：2050-2055，2007

42) Kawaguchi Y, Nakamura Y, Matsumoto I, et al : Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis : contribution to severe gastrointestinal tract dysmotility. Ann Rheum Dis　68：710-714，2009

43) Hendel L, Hage E, Hendel J, et al : Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther　6：565-577，1992